Symptoms of overdose include clumsiness or unsteadiness, coma, severe dizziness, severe drowsiness, severe nausea, and problems with vision.
Paramethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paramethadione. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Paramethadione. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Paramethadione. |
| Hydrocodone | Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Paramethadione. |
| Magnesium sulfate | The therapeutic efficacy of Paramethadione can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Paramethadione may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Paramethadione. |
| Mirtazapine | Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Paramethadione. |
| Orphenadrine | Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Paramethadione. |
| Pramipexole | Paramethadione may increase the sedative activities of Pramipexole. |
| Ropinirole | Paramethadione may increase the sedative activities of Ropinirole. |
| Rotigotine | Paramethadione may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Paramethadione. |
| Sodium oxybate | Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Paramethadione. |
| Thalidomide | Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Mefloquine | The therapeutic efficacy of Paramethadione can be decreased when used in combination with Mefloquine. |
| Mianserin | The therapeutic efficacy of Paramethadione can be decreased when used in combination with Mianserin. |
| Orlistat | Orlistat can cause a decrease in the absorption of Paramethadione resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Topotecan | Paramethadione may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Paramethadione. |
| Mifepristone | The serum concentration of Paramethadione can be increased when it is combined with Mifepristone. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Paramethadione. |
| Ethanol | Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Paramethadione. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Paramethadione is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Paramethadione is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Paramethadione is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Paramethadione is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Paramethadione is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Paramethadione is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Paramethadione is combined with Sibutramine. |
| Escitalopram | The risk or severity of adverse effects can be increased when Paramethadione is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Paramethadione is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Paramethadione is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Paramethadione is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Paramethadione is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Paramethadione is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Paramethadione is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Paramethadione is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Paramethadione is combined with Alaproclate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Paramethadione. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with Paramethadione. |
| Propiomazine | The risk or severity of CNS depression can be increased when Paramethadione is combined with Propiomazine. |
| Maprotiline | The risk or severity of CNS depression can be increased when Paramethadione is combined with Maprotiline. |
| Tolterodine | The metabolism of Tolterodine can be decreased when combined with Paramethadione. |
| Desipramine | The risk or severity of CNS depression can be increased when Paramethadione is combined with Desipramine. |
| Pizotifen | The risk or severity of CNS depression can be increased when Paramethadione is combined with Pizotifen. |
| Dosulepin | The risk or severity of CNS depression can be increased when Paramethadione is combined with Dosulepin. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with Paramethadione. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with Paramethadione. |
| Quetiapine | The risk or severity of CNS depression can be increased when Paramethadione is combined with Quetiapine. |
| Doxepin | The risk or severity of CNS depression can be increased when Paramethadione is combined with Doxepin. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Paramethadione is combined with Cocaine. |
| Quinidine | The metabolism of Paramethadione can be decreased when combined with Quinidine. |
| Zopiclone | The risk or severity of adverse effects can be increased when Paramethadione is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Paramethadione. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Paramethadione. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Paramethadione. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Paramethadione. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Paramethadione. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Paramethadione. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Paramethadione. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Paramethadione. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Paramethadione. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Paramethadione. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Paramethadione. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Paramethadione. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Paramethadione. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Paramethadione. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Paramethadione. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Paramethadione. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with Paramethadione. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Paramethadione. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Paramethadione. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Paramethadione. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Paramethadione. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Paramethadione. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Paramethadione. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Paramethadione. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Paramethadione. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Paramethadione. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with Paramethadione. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Paramethadione. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Paramethadione. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Paramethadione. |
| Clozapine | The metabolism of Paramethadione can be decreased when combined with Clozapine. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with Paramethadione. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Paramethadione. |
| Palonosetron | The risk or severity of CNS depression can be increased when Palonosetron is combined with Paramethadione. |
| Sulpiride | The risk or severity of CNS depression can be increased when Sulpiride is combined with Paramethadione. |